Condition: IgAN · IgAVN · Immunoglobulin A Nephropathy · Sponsor: Alexion Pharmaceuticals, Inc.
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Palo Alto, California, United States | Not Yet Recruiting |
| Research Site | Aurora, Colorado, United States | Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Shanghai, China | Recruiting |
| Research Site | Genova, Italy | Recruiting |
| Research Site | Roma, Italy | Recruiting |
| Research Site | Torino, Italy | Recruiting |
| Research Site | Wakayama, Japan | Recruiting |
| Research Site | Seoul, South Korea | Recruiting |
| Research Site | Almería, Spain | Not Yet Recruiting |
| Research Site | Barcelona, Spain | Recruiting |
| Research Site | Barcelona, Spain | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07024563